Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Tarsus reported Q2 revenue of $173.9 million, up 69% year-over-year, driven by record XDEMVY sales and improved gross-to-net performance. The company raised full-year 2026 XDEMVY sales guidance to $685-705 million and announced a pending acquisition of Alkeus Pharmaceuticals to secure a Phase 3 asset for Stargardt disease.
Key figures
- Revenue
- 173900000
- Guidance
- FY26 XDEMVY net product sales $685-705 million
- Revenue Yoy
- 69%
- Gross margin
- 93%
- Cash position
- 449700000
- Financing proceeds
- 125000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.